SkinBioTherapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Net Income	-0.47	-0.72	-2.95	-3.01	-2.99	-1.5
Depreciation & Amortization	0.54	0.43	0.18	0.05	0.04	0.01
Stock-Based Compensation	-	-	-	0	0.05	0.06
Other Adjustments	-0.63	-0.41	0.04	-	-	-
Change in Receivables	-0.92	-0.75	0.17	-0.05	0.13	-0.2
Changes in Inventories	-0.1	0.01	0.1	0.09	-0.12	-
Changes in Accounts Payable	-0.38	0.17	-0.44	0.02	0.1	0.07
Changes in Income Taxes Payable	-	0.03	0.18	0.26	0.12	-
Operating Cash Flow	-1.94	-1.24	-2.73	-2.65	-2.67	-1.56
Operating Cash Flow Growth	-	-	-	-	-	-
Capital Expenditures	-0.03	-0.01	-0.01	-0.09	-	-
Purchases of Intangible Assets	-0.11	-0.15	-0.17	-0.08	-0.1	-0.11
Cash Acquisitions	-0.05	-1.46	-2.1	-	-	-
Other Investing Activities	0	-	-0.01	-	-	-0
Investing Cash Flow	-0.18	-1.62	-2.3	-0.17	-0.1	-0.11
Long-Term Debt Issued	-	0.95	1.47	-	-	-
Long-Term Debt Repaid	-0.15	-0.11	-0.04	-0.04	-0.04	-0
Net Long-Term Debt Issued (Repaid)	-0.15	0.84	1.43	-0.04	-0.04	-0
Issuance of Common Stock	4.24	6.06	3.12	2.35	-	4.12
Net Common Stock Issued (Repurchased)	4.24	6.06	3.12	2.35	-	4.12
Other Financing Activities	-0.08	-0.06	-0.04	-	-	-
Financing Cash Flow	4.01	6.83	4.51	2.32	-0.04	4.12
Net Cash Flow	1.89	3.98	-0.51	-0.49	-2.8	2.45
Free Cash Flow	-1.97	-1.24	-2.74	-2.73	-2.67	-1.56
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-44.18%	-32.08%	-226.80%	-2071.02%	-3575.44%	-
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.02	-0.02	-0.01
Levered Free Cash Flow	-1.63	-0.27	-1.44	-2.54	-2.69	-1.36
Unlevered Free Cash Flow	-2.12	-1.52	-2.83	-2.5	-2.65	-1.35